克拉斯
结直肠癌
免疫疗法
微卫星不稳定性
神经母细胞瘤RAS病毒癌基因同源物
免疫检查点
DNA错配修复
医学
癌症免疫疗法
生物标志物
免疫原性
癌症
个性化医疗
封锁
肿瘤微环境
免疫系统
免疫学
生物信息学
生物
内科学
等位基因
基因
遗传学
受体
微卫星
作者
Jaime González‐Montero,Carlos I Rojas,Mauricio Burotto
出处
期刊:Oncologist
[AlphaMed Press]
日期:2024-06-26
卷期号:29 (10): 824-832
被引量:36
标识
DOI:10.1093/oncolo/oyae152
摘要
Colorectal cancer (CRC) is a major cause of cancer-related deaths globally. While treatment advancements have improved survival rates, primarily through targeted therapies based on KRAS, NRAS, and BRAF mutations, personalized treatment strategies for CRC remain limited. Immunotherapy, mainly immune checkpoint blockade, has shown efficacy in various cancers but is effective in only a small subset of patients with CRC with deficient mismatch repair (dMMR) proteins or high microsatellite instability (MSI). Recent research has challenged the notion that CRC is immunologically inert, revealing subsets with high immunogenicity and diverse lymphocytic infiltration. Identifying precise biomarkers beyond dMMR and MSI is crucial to expanding immunotherapy benefits. Hence, exploration has extended to various biomarker sources, such as the tumor microenvironment, genomic markers, and gut microbiota. Recent studies have introduced a novel classification system, consensus molecular subtypes, that aids in identifying patients with CRC with an immunogenic profile. These findings underscore the necessity of moving beyond single biomarkers and toward a comprehensive understanding of the immunological landscape in CRC, facilitating the development of more effective, personalized therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI